vs

Side-by-side financial comparison of MEDIFAST INC (MED) and MAXLINEAR, INC (MXL). Click either name above to swap in a different company.

MAXLINEAR, INC is the larger business by last-quarter revenue ($137.2M vs $75.1M, roughly 1.8× MEDIFAST INC). On growth, MAXLINEAR, INC posted the faster year-over-year revenue change (43.0% vs -36.9%). Over the past eight quarters, MAXLINEAR, INC's revenue compounded faster (22.1% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.

MED vs MXL — Head-to-Head

Bigger by revenue
MXL
MXL
1.8× larger
MXL
$137.2M
$75.1M
MED
Growing faster (revenue YoY)
MXL
MXL
+79.9% gap
MXL
43.0%
-36.9%
MED
Faster 2-yr revenue CAGR
MXL
MXL
Annualised
MXL
22.1%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MED
MED
MXL
MXL
Revenue
$75.1M
$137.2M
Net Profit
$-45.1M
Gross Margin
69.4%
57.5%
Operating Margin
-10.4%
30.0%
Net Margin
-32.9%
Revenue YoY
-36.9%
43.0%
Net Profit YoY
-203.0%
EPS (diluted)
$-1.64
$-0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
MXL
MXL
Q1 26
$137.2M
Q4 25
$75.1M
$136.4M
Q3 25
$89.4M
$126.5M
Q2 25
$105.6M
$108.8M
Q1 25
$115.7M
$95.9M
Q4 24
$119.0M
$92.2M
Q3 24
$140.2M
$81.1M
Q2 24
$168.6M
$92.0M
Net Profit
MED
MED
MXL
MXL
Q1 26
$-45.1M
Q4 25
$-14.9M
Q3 25
$-2.3M
$-45.5M
Q2 25
$2.5M
$-26.6M
Q1 25
$-772.0K
$-49.7M
Q4 24
$-57.8M
Q3 24
$1.1M
$-75.8M
Q2 24
$-8.2M
$-39.3M
Gross Margin
MED
MED
MXL
MXL
Q1 26
57.5%
Q4 25
69.4%
57.6%
Q3 25
69.5%
56.9%
Q2 25
72.6%
56.5%
Q1 25
72.8%
56.1%
Q4 24
74.1%
55.6%
Q3 24
75.4%
54.4%
Q2 24
73.2%
54.6%
Operating Margin
MED
MED
MXL
MXL
Q1 26
30.0%
Q4 25
-10.4%
-10.9%
Q3 25
-4.6%
-32.7%
Q2 25
-1.0%
-22.6%
Q1 25
-1.1%
-48.0%
Q4 24
0.6%
-44.7%
Q3 24
1.5%
-82.3%
Q2 24
-4.7%
-44.4%
Net Margin
MED
MED
MXL
MXL
Q1 26
-32.9%
Q4 25
-10.9%
Q3 25
-2.5%
-36.0%
Q2 25
2.3%
-24.4%
Q1 25
-0.7%
-51.8%
Q4 24
-62.8%
Q3 24
0.8%
-93.4%
Q2 24
-4.8%
-42.7%
EPS (diluted)
MED
MED
MXL
MXL
Q1 26
$-0.52
Q4 25
$-1.64
$-0.17
Q3 25
$-0.21
$-0.52
Q2 25
$0.22
$-0.31
Q1 25
$-0.07
$-0.58
Q4 24
$0.08
$-0.68
Q3 24
$0.10
$-0.90
Q2 24
$-0.75
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
MXL
MXL
Cash + ST InvestmentsLiquidity on hand
$167.3M
$61.1M
Total DebtLower is stronger
$123.8M
Stockholders' EquityBook value
$198.9M
$454.2M
Total Assets
$248.0M
$771.3M
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
MXL
MXL
Q1 26
$61.1M
Q4 25
$167.3M
$72.8M
Q3 25
$173.5M
$111.9M
Q2 25
$162.7M
$108.6M
Q1 25
$164.6M
$102.8M
Q4 24
$162.3M
$118.6M
Q3 24
$170.0M
$148.5M
Q2 24
$163.5M
$185.1M
Total Debt
MED
MED
MXL
MXL
Q1 26
$123.8M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
MED
MED
MXL
MXL
Q1 26
$454.2M
Q4 25
$198.9M
$451.9M
Q3 25
$214.7M
$464.7M
Q2 25
$216.0M
$488.3M
Q1 25
$211.0M
$493.2M
Q4 24
$210.1M
$516.3M
Q3 24
$207.3M
$556.9M
Q2 24
$205.3M
$617.3M
Total Assets
MED
MED
MXL
MXL
Q1 26
$771.3M
Q4 25
$248.0M
$796.4M
Q3 25
$268.2M
$808.1M
Q2 25
$269.3M
$863.7M
Q1 25
$280.0M
$855.3M
Q4 24
$284.2M
$864.6M
Q3 24
$291.2M
$895.3M
Q2 24
$293.5M
$973.2M
Debt / Equity
MED
MED
MXL
MXL
Q1 26
0.27×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
MXL
MXL
Operating Cash FlowLast quarter
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
MXL
MXL
Q1 26
Q4 25
$-5.3M
$10.4M
Q3 25
$12.1M
$10.1M
Q2 25
$-3.4M
$10.5M
Q1 25
$3.4M
$-11.4M
Q4 24
$-4.9M
$-27.8M
Q3 24
$9.1M
$-30.7M
Q2 24
$13.1M
$-2.7M
Free Cash Flow
MED
MED
MXL
MXL
Q1 26
Q4 25
$-6.6M
$6.7M
Q3 25
$10.8M
$4.4M
Q2 25
$-4.8M
$9.3M
Q1 25
$1.9M
$-13.4M
Q4 24
$-7.2M
$-30.0M
Q3 24
$7.7M
$-34.9M
Q2 24
$11.1M
$-5.7M
FCF Margin
MED
MED
MXL
MXL
Q1 26
Q4 25
-8.8%
4.9%
Q3 25
12.0%
3.5%
Q2 25
-4.5%
8.6%
Q1 25
1.6%
-14.0%
Q4 24
-6.1%
-32.6%
Q3 24
5.5%
-43.0%
Q2 24
6.6%
-6.2%
Capex Intensity
MED
MED
MXL
MXL
Q1 26
Q4 25
1.8%
2.7%
Q3 25
1.5%
4.5%
Q2 25
1.3%
1.1%
Q1 25
1.3%
2.1%
Q4 24
1.9%
2.4%
Q3 24
1.0%
5.1%
Q2 24
1.1%
3.3%
Cash Conversion
MED
MED
MXL
MXL
Q1 26
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons